Tech Center 1600 • Art Units: 1645
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17757441 | METHOD FOR THE FERMENTATIVE PRODUCTION OF GUANIDINOACETIC ACID | Final Rejection | Evonik Operations GmbH |
| 17912331 | Attenuated Mycoplasma Bacteria | Final Rejection | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS |
| 17996013 | MONOCLONAL ANTIBODY AND USES THEREOF FOR THE TREATMENT AND DIAGNOSIS OF MULTIDRUG-RESISTANT PATHOGENIC BACTERIAL INFECTIONS | Non-Final OA | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
| 18471276 | New Core/Shell Materials of Nanowire/Graphene on Low-Cost RFID Tags for Rapidly Sensing Live Cell Metabolites at Single-Cell Sensitivity | Final Rejection | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS |
| 18045599 | MODIFIED NANOPORES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Non-Final OA | Oxford Nanopore Technologies PLC |
| 17426557 | IMMUNOCHROMATOGRAPHIC TEST STRIP FOR EXTRACTING AND MEASURING SUGAR CHAIN ANTIGENS, CAPABLE OF CONTROLLING THE DEVELOPMENT OF SPECIMEN BY IMPREGNATING HYDROPHILIC MATERIAL WITH NITRITE OR SOLID ACID REAGENT | Final Rejection | Denka Company Limited |
| 18001551 | Shigella-Tetravalent (Shigella4V) Bioconjugate | Non-Final OA | GlaxoSmithKline Biologicals SA |
| 18008767 | GBS FERRITIN NANOPARTICLES | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18008777 | BACTERIAL IMMUNIZATION USING NANOPARTICLE VACCINE | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17588425 | VACCINE | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18557471 | COMBINATION PRODUCT AND METHODS FOR PREVENTING THE EMERGENCE OF ANTIBIOTIC-RESISTANT BACTERIA UNDER ANTIBIOTIC TREATMENT | Non-Final OA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS |
| 18512470 | METHOD OF REDUCING URIC ACID BY USING LACTOBACILLUS PARACASEI LT12 | Non-Final OA | SHANGHAI LYTONE BIOCHEMICALS, LTD. |
| 18498630 | APPLICATION OF LACTOBACILLUS FERMENTUM IN PREPARING PRODUCTS FOR PREVENTING AND/OR TREATING THROMBUS | Non-Final OA | Thankcome Biological Science and Technology (Suzhou) Co., Ltd. |
| 17632449 | METHODS AND COMPOSITIONS FOR CULTURING HEMOGLOBIN-DEPENDENT BACTERIA | Final Rejection | Evelo Biosciences, Inc. |
| 18550626 | METHOD FOR THE IN VITRO DIAGNOSIS OF INFECTION | Non-Final OA | ORIGINAL G B.V. |
| 17630841 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITIONS AND METHODS OF USING THE SAME | Non-Final OA | SK BIOSCIENCE CO., LTD. |
| 18261598 | BIOLOGICAL MARKER OF INTESTINAL DYSBIOSIS, USEFUL FOR PREDICTING THE RESPONSE OF A CANCER PATIENT TO AN ANTI-PDI DRUG | Non-Final OA | EVERIMMUNE |
| 17959546 | TOLL-LIKE RECEPTOR 2 AGONISTS AND VACCINES AND USES THEREOF | Non-Final OA | The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy |
| 17923346 | METHOD FOR LIQUEFYING A RESPIRATORY SAMPLE AND FOR THE SUBSEQUENT DETECTION OF RESPIRATORY INFECTIONS IN SAID SAMPLE | Non-Final OA | SERVEI DE SALUT DE LES ILLES BALEARS - IBSALUT |
| 16933720 | METHOD FOR ASSESSING THE LETHALITY AND THE LEVEL OF CROSS CONTAMINATION CONTROL OF A PROCESS NON-INVASIVELY | Non-Final OA | Fremonta Corporation |
| 17312820 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE | Non-Final OA | Biological E Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy